AP2000001977A0 - The process for manufacturing topical opthalmic preparations without systemic effects. - Google Patents

The process for manufacturing topical opthalmic preparations without systemic effects.

Info

Publication number
AP2000001977A0
AP2000001977A0 APAP/P/2000/001977A AP2000001977A AP2000001977A0 AP 2000001977 A0 AP2000001977 A0 AP 2000001977A0 AP 2000001977 A AP2000001977 A AP 2000001977A AP 2000001977 A0 AP2000001977 A0 AP 2000001977A0
Authority
AP
ARIPO
Prior art keywords
topical
systemic
preparations
timolol
clonidine
Prior art date
Application number
APAP/P/2000/001977A
Other languages
English (en)
Inventor
Bakulesh Mafatlal Khamar
Original Assignee
Bakulesh Mafatlal Khamar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bakulesh Mafatlal Khamar filed Critical Bakulesh Mafatlal Khamar
Publication of AP2000001977A0 publication Critical patent/AP2000001977A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
APAP/P/2000/001977A 1999-02-03 2000-02-02 The process for manufacturing topical opthalmic preparations without systemic effects. AP2000001977A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN90BO1999 IN185228B (el) 1999-02-03 1999-02-03
PCT/IN2000/000008 WO2000049990A2 (en) 1999-02-03 2000-02-02 The process for manufacturing topical ophthalmic preparations without systemic effects

Publications (1)

Publication Number Publication Date
AP2000001977A0 true AP2000001977A0 (en) 2000-12-31

Family

ID=11077485

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2000/001977A AP2000001977A0 (en) 1999-02-03 2000-02-02 The process for manufacturing topical opthalmic preparations without systemic effects.

Country Status (11)

Country Link
EP (1) EP1139970A2 (el)
AP (1) AP2000001977A0 (el)
AU (1) AU4429100A (el)
BR (1) BR0004530A (el)
CA (1) CA2326690A1 (el)
EA (1) EA200000918A1 (el)
ID (1) ID28121A (el)
IL (1) IL138824A0 (el)
IN (1) IN185228B (el)
WO (1) WO2000049990A2 (el)
ZA (1) ZA200006252B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
AU2005220199B2 (en) * 2000-07-14 2007-03-08 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
NZ521185A (en) * 2000-07-14 2005-02-25 Allergan Inc Compositions containing alpha-2-adrenergic agonist components
DE10132876A1 (de) * 2001-07-06 2003-01-30 Medproject Pharma Entwicklungs Zweiphasige, tropfbare Hydrogele zur Anwendung am Auge
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
ES2647618T3 (es) 2004-05-25 2017-12-22 Galderma Pharma S.A. Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
FR2977493B1 (fr) 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
WO2014127243A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
GB202110420D0 (en) * 2021-07-20 2021-09-01 Rosemont Pharmaceuticals Ltd Liquid pharmaceutical composition of clonidine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) * 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
DD294174A5 (de) * 1990-05-04 1991-09-26 Sigrid Keipert Ophthalmika mit retardwirkung und ein neues verfahren zu ihrer herstellung
FR2678832B1 (fr) * 1991-07-10 1995-03-17 Europhta Sa Laboratoire Nouvelles compositions ophtalmiques a resorption amelioree et leurs procedes de preparation.
FR2679773A1 (fr) * 1991-07-30 1993-02-05 Merck Sharp & Dohme Preparation ophtalmique contenant un agent osmotique acceptable antimicrobien.
DE19614823A1 (de) * 1996-04-15 1997-10-16 Mann Gerhard Chem Pharm Fab Ophthalmische Zusammensetzung mit verlängerter Verweilzeit am Auge

Also Published As

Publication number Publication date
IN185228B (el) 2000-12-09
WO2000049990A3 (en) 2001-07-26
AU4429100A (en) 2000-09-14
ZA200006252B (en) 2001-11-29
EA200000918A1 (ru) 2001-10-22
IL138824A0 (en) 2001-10-31
ID28121A (id) 2001-05-03
EP1139970A2 (en) 2001-10-10
WO2000049990A2 (en) 2000-08-31
BR0004530A (pt) 2001-04-03
CA2326690A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
AP2000001977A0 (en) The process for manufacturing topical opthalmic preparations without systemic effects.
WO2004071469A3 (en) Methods of administering a dermatological agent to a subject
US9216167B2 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
AU2003301747A1 (en) Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
MXPA05008140A (es) Una composicion farmaceutica de rapida accion.
CA2460140A1 (en) Compositions for treatment of common cold
BR0313575A (pt) Método de transporte transdermal de produtos farmacêuticos topicamente administrados, veìculo, composição de veìculo, composição farmacêutica e uso de um ou mais complexos de derivados de fosfato de compostos farmaceuticamente aceitáveis lipofìlicos com outros excipientes
WO2006093784A3 (en) Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents
AU2001288460A1 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
El Maalouf et al. Could we expect to improve survival in small cell lung cancer?
Blijham et al. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study
US6444676B1 (en) Use of PARP inhibitors in the treatment of glaucoma
CA2310950A1 (en) An efficacious dosage regiment of galantamine that reduces side effects
WO2005011618A3 (en) Methods for the treatment of male and female sexual dysfunction
AU2003290015A1 (en) Mastitis treatment
WO2004080414A3 (en) Composition and method for treating inflammations by reducing c-reactive protein
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
WO2003047697A3 (en) Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
MX2022013391A (es) Pauta posologica para el tratamiento del cancer.
US20010025027A1 (en) Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
WO2004030623A3 (en) Nitroxide radioprotector formulations and methods of use
WO2006098754A3 (en) A suspension comprising an active principle, a suspending vehicle, a density-modifying solid with an increased physical stability
WO2000061171A3 (en) Uses of mammalian ox2 protein and related reagents